RE:hang your hats on this paragraph folks.Themandyman wrote: “The clinical activity of PBI-4050 has now been confirmed in the liver, the heart, the kidney, and in the fat tissue in the AS patients, stated Pierre Laurin, President and Chief Executive Officer of Prometic. “We look forward to presenting these detailed trial results this summer at meetings scheduled with European and U.S. regulatory authorities to determine the clinical-regulatory pathway for PBI-4050 in Alstrm syndrome.”
Jargon like this from Pierre has less credibility than it did in the past. Remember, they were in “constant contact with the FDA” for Pg and now we
are looking at a crippling YEAR LONG delay there. You think he can deliver anything on 4050?? Is Pierre buying any shares???